
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. has demonstrated a positive trajectory through the promising data released from multiple Phase 2 studies, particularly highlighting the effectiveness of its leading product, Ampligen, in treating post-COVID conditions and colorectal cancer. The company’s strategic focus on pancreatic cancer and the successful outcomes of prior studies suggest significant potential for future advancements, which could serve as key catalysts for stock performance. Overall, AIM ImmunoTech's valuation reflects a strategic balance of inherent risks against the substantial growth prospects and substantial upside opportunities presented by their innovative therapeutics.
Bears say
AIM ImmunoTech Inc experienced significant net losses, reporting a loss of $3.3 million or an EPS of $(1.57) in comparison to consensus estimates, signaling operational challenges and financial instability. The company’s prior quarterly figures reflected a net loss of $4.2 million with an EPS of $(1.39), again falling short of expectations, which raises concerns about its profitability and financial health. Additionally, several key risks threaten the company's outlook, including balance sheet liquidity issues, the potential failure of product candidates in clinical trials, challenges in obtaining regulatory approvals, and difficulties in commercialization and reimbursement, all exacerbated by competitive and macroeconomic pressures.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares